Vanguard Health Care ETF (VHT) Latest News, Market Updates & Sentiment | Edgen
Back
Home
Stock
VHT
Vanguard Health Care ETF (VHT)
VHT Stock Price Chart
VHT
Vanguard Health Care ETF
$283.38
2.94%
$8.11
At close: Jun 04, 16:00:00 GMT-4
$285
0.57%
$1.62
Pre-market: Jun 05, 08:54:09 GMT-4
Overview
Forecast
Holdings
News
Article
Key Stats
Prev.Close
$275.27
Open
$279.78
Day's Range
$279.78 - $285
52 week range
$237.23 - $298.6
Volume
254.6K
Avg.Volume
209.0K
Dividend yield
1.68%
Net Assets
$0
NAV
--
Expense Ratio
--
Shares Outstanding
58.7M
What is VHT?
VHT was created on 2004-01-26 by Vanguard. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 16297.24m in AUM and 403 holdings. The fund tracks a market-cap-weighted index of US healthcare stocks.
Markets
US Stocks
HK Stocks
News
Analyst Moves
Market Moves
Hong Kong IPO
Earnings
AI & Technology
Macro & Policy
Terms of Use
Privacy Policy
Sitemap
© 2026 Edgen Powered by
Amgen eyes 2026 springboard year on 6% revenue growth, MariTide
Jun 05 2026, 05:39
Keymed Bio receives $257M upfront from Gilead's Ouro buyout
Jun 05 2026, 04:44
Dow surges 874 points to record close as investors rotate from AI chips
Jun 04 2026, 20:39
UnitedHealth rallies 5% after Bank of America upgrade on margin outlook
Jun 04 2026, 19:41
Eli Lilly and Novo Nordisk surge 5% as weight-loss drug sector rallies
Jun 04 2026, 16:13
Dow Jones rises 1.53% to 51,460, setting new record high
Jun 04 2026, 14:12
NVIDIA and Bezos back AI biology as $58B computational market takes off
Jun 03 2026, 16:42
Eli Lilly halves €2.3B Germany investment plan amid strategic pullback
Jun 03 2026, 15:28
Amgen wins EU approval for Imdylltra as lung cancer drug cuts death risk 40%
Jun 02 2026, 16:41
UnitedHealth to cut 66% of pediatric prior authorizations by year-end
Jun 01 2026, 13:35
Novo Nordisk Wegovy pill outsells Lilly's Foundayo 9-to-1 as growth slows
Jun 01 2026, 13:07
J&J's RYBREVANT FASPRO posts 42% response rate in head and neck cancer
May 31 2026, 14:10
J&J's Erleada cuts metastasis risk by 20% in prostate cancer trial
May 31 2026, 12:39
Johnson & Johnson meets 2 primary endpoints in Phase 3 prostate cancer trial
May 31 2026, 12:10
Eli Lilly secures PBM coverage for obesity drugs, expanding access to millions
May 28 2026, 10:58
AbbVie's Decnupaz wins FDA approval with 69% response rate in rare cancer
May 27 2026, 22:39
Dow climbs 92 points as AI chip rally offsets Iran tensions
May 26 2026, 14:09
Intuitive Surgical Ion procedures jump 39% on clinical validation
May 25 2026, 16:47